Intrinsic ALK-TKI Resistance Due to MetCoamplification in ALK plus NSCLC, Effectively Treated by Alectinib-crizotinib Combination

被引：0
|
作者：
Urbanska, E. M. [1 ]
Melchior, L. C. [1 ]
Sorensen, J. B. [1 ,2 ]
Santoni-Rugiu, E. [1 ,2 ]
机构：
[1] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
de novo MET-amplification; intrinsic ALK-TKI resistance; TKIs combination;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.12
引用
收藏
页码：S645 / S646
页数：2
相关论文
共 50 条
  • [31] Identification and monitoring of a high-level MET amplification in CTCs and cfTNA in an ALK-rearranged NSCLC patient treated with crizotinib, alectinib and ceritinib
    Berger, L. A.
    Velthaus, J. L.
    Janning, M.
    Schatz, S.
    Falk, M.
    Iglauer, P.
    Simon, R.
    Cao, R.
    Bramlett, K.
    Buson, G.
    Petrini, E.
    Forcato, C.
    Tiemann, M.
    Sauter, G.
    Bokemeyer, C.
    Reck, M.
    Riethdorf, S.
    Pantel, K.
    Wikman, H.
    Loges, S.
    CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (03) : 183 - 183
  • [32] CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK plus NSCLC
    de Castro, J.
    Novello, S.
    Mazieres, J.
    Oh, I-J.
    Migliorino, M. R.
    Helland, A.
    Dziadziuszko, R.
    Griesinger, F.
    de Marinis, F.
    Zeaiter, A.
    Cardona, A.
    Balas, B.
    Johannsdottir, H.
    Chlistalla, M.
    Smoljanovic, V.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)
    Kim, Young
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S378 - S379
  • [34] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC).
    Yoshioka, Hiroshige
    Hida, Toyoaki
    Nokihara, Hiroshi
    Morise, Masahiro
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Kumagai, Toru
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Yoshimoto, Takuya
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK plus NSCLC Treated with Crizotinib vs Chemotherapy
    Lu, You
    Zhou, Jianying
    Chung, Chin-Hee
    Masters, Elizabeth
    Wilner, Keith
    Selaru, Paulina
    Tang, Yiyun
    Wu, Yi Long
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1167
  • [36] Clinical characteristics of ALK plus NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.
    Otterson, Gregory Alan
    Riely, Gregory J.
    Shaw, Alice Tsang
    Crino, Lucio
    Kim, Dong-Wan
    Martins, Renato
    Salgia, Ravi
    Zhou, Caicun
    Solomon, Benjamin J.
    Wilner, Keith D.
    Polli, Anna
    Tang, Yiyun
    Bartlett, Cynthia Huang
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naive anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Halawah, Hala
    Calamia, Matthias
    Gulick, Dexter
    Manasrah, AlMothana
    Alkhdour, Odai
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK plus NSCLC.
    Camidge, D. Ross
    Peters, Solange
    Mok, Tony
    Gadgeel, Shirish M.
    Cheema, Parneet K.
    Pavlakis, Nick
    De Marinis, Filippo
    Stroyakovskiy, Daniil L.
    Cho, Byoung Chul
    Zhang, Li
    Moro-Sibilot, Denis
    Zeaiter, Ali Hassan
    Mitry, Emmanuel
    Balas, Bogdana
    Mueller, Barbara
    Shaw, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK plus non-small cell lung cancer (NSCLC)
    Wolf, J.
    Oh, I-J.
    Mazieres, J.
    de Castro, J.
    Revil, C.
    Kotb, A.
    Johansdottir, H.
    Zeaiter, A.
    Novello, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC).
    Seto, Takashi
    Nishio, Makoto
    Hida, Toyoaki
    Nokihara, Hiroshi
    Morise, Masahiro
    Kim, Young Hak
    Azuma, Koichi
    Takiguchi, Yuichi
    Yoshioka, Hiroshige
    Kumagai, Toru
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Asakawa, Takashi
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345